Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and raises the price target from $290 to $300.
Oppenheimer raises Amgen (NASDAQ:AMGN) price target from $290 to $300 Read Post »
Pfizer Secures Unconditional EU Antitrust Approval For $43B Seagen Deal.
Pfizer Secures Unconditional EU Antitrust Approval For $43B Seagen Deal Read Post »
Intuitive Surgical (ISRG) reported late Thursday Q3 non-GAAP earnings of $1.46 per diluted share, up from $1.19 a year earlier. Analysts polled by Capital IQ expected $1.42. Revenue for the quarter ended Sept. 30 was $1.74 billion, up from $1.56 billion a year earlier. Analysts surveyed by Capital IQ expected $1.77 billion.
Intuitive Surgical Q3 Non-GAAP Earnings, Revenue Increase Read Post »
Intuitive Surgical posted higher third-quarter profit due to a double-digit increase in procedures using its robotic-surgery system. The Sunnyvale, Calif.-based company on Thursday reported a profit of $415.7 million , or $1.16 share, compared with a profit of $324 million, or 90 cents a share, in the same quarter last year. Excluding one-time items, the company reported earnings of $1.46 a share. Analysts recently polled by FactSet expected $1.42 a share. Revenue rose 12% to $1.74 billion, compared with analyst expectations of $1.77 billion. Instruments and accessories revenue rose by 23% to $1.07 billion, helped by a 19% increase in procedures using its da Vinci system and higher prices. The company said its installed base of da Vinci systems stood at 8,285 at the end of the third-quarter, up 13% from a year ago.
Intuitive Surgical 3Q Profit Up On More Procedures Using Its Robotic-Surgery System Read Post »
By Eleanor Laise New ultrasound technology has potential to regulate metabolic function, early-stage clinical research shows GE HealthCare Technologies Inc. (GEHC) on Thursday said it is teaming up with Novo Nordisk (NVO) to develop an ultrasound treatment for type 2 diabetes and obesity. The collaboration is focused on peripheral focused ultrasound, a new technology with potential to regulate metabolic function–without drugs, GE HealthCare said in a release. Early-stage clinical research suggests this type of ultrasound can affect diabetes patients’ glucose metabolism by stimulating nerve pathways, the company said. More than 37 million people in the U.S. have diabetes, according to the Centers for Disease Control and Prevention, and 90% to 95% of them have type 2 diabetes. “This collaboration with Novo Nordisk opens a path to evolve ultrasound from a means of screening and diagnosis into therapy, as well,” Roland Rott, president and CEO of GE HealthCare’s ultrasound business, said
GE HealthCare Teams up With Novo Nordisk to Treat Diabetes Without Drugs Read Post »
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our target price by $20 to $634, 52.7x our 2024 EPS, a premium to LLY’s historical forward P/E average, justified by the company’s strong revenue and earnings growth potential. We keep our 2023 EPS estimate at $9.87 and our 2024 EPS at $12.02. Following the strong rally in LLY shares since the beginning of September (+8%), we are seeing some profit-taking activity in recent days, in our view. However, we continue to have a positive opinion on LLY. We think the company has solid long-term prospects, driven by internal innovation, but also by its recent acquisitions (Versanis Bio, Sigilon, and Dice Therapeutics), which we believe will strategically expand its portfolio.
CFRA Lowers Opinion On Shares Of Eli Lilly To Buy From Strong Buy Read Post »
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We trim our 12-month target price to $113 from $130, 24.4x our ’24 EPS forecast, in line with ABT’s historical forward average. We lift our ’23 EPS estimate by $0.03 to $4.43 and maintain our ’24 estimate of $4.63. Q3 adj. EPS of $1.14 vs. $1.15 beat the consensus view by $0.04, driven by sales growth from Nutrition (+16% Y/Y) due to continued market share recapture in the U.S. infant formula business, where ABT has now reclaimed the leadership position, in addition to growth in Medical Device sales (+17% Y/Y), aided by FreeStyle Libre sales growth of 28% in Q3. ABT sees a growing number of Libre users in the U.S. using Libre in combination with GLP-1 medications — a view that these approaches are complimentary as
CFRA Keeps Buy Opinion On Shares Of Abbott Laboratories Read Post »
Abbott Projects FY23 Adjusted EPS Of $4.42-$4.46 Versus Prior Guidance Of $4.30-$4.50 And Consensus Of $4.18.
ABBOTT Posts Q3 EPS $1.14, vs. Street Est of $1.10。
ABBOTT Posts Q3 EPS $1.14, vs. Street Est of $1.10 Read Post »
Johnson & Johnson (NYSE: JNJ) Exec Says Co Expects To File For Regulatory Approval For Lung Cancer Therapy In 2025.
Wells Fargo analyst Mohit Bansal maintains Pfizer (NYSE:PFE) with a Equal-Weight and lowers the price target from $39 to $35.
Wells Fargo lowers Pfizer (NYSE:PFE) price target from $39 to $35 Read Post »
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our target price at $162, 14.8x our 2024 EPS estimate, below JNJ’s five-year historical forward P/E average. We lift our 2023 EPS estimate by $0.14 to $10.18 and keep our 2024 EPS estimate at $10.94. Q3 EPS of $2.66 vs. $2.23 (+19.3% Y/ Y) was $0.16 above our estimate and $0.14 above consensus. Q3 revenues of $21.4B outperformed expectations, up 6.8% Y/Y, $302M above consensus, due to better-than-anticipated sales performance in the U.S. (+11.1% Y/Y), offsetting slow growth internationally (+1.6% Y/Y). Following the separation with Kenvue, JNJ reports two main businesses: Pharma, going forward referred as Innovative Medicine (65% of total, +5.1% Y/Y), and Medtech (35% of total, +10% Y/Y). Robust growth in Medtech was driven by Interventional Solutions (+47% Y/Y), which also includes contributions
CFRA Retains Hold Opinion On Shares Of Johnson & Johnson Read Post »